|Bid||3.9400 x 4000|
|Ask||4.0000 x 1300|
|Day's Range||3.7400 - 4.0000|
|52 Week Range||1.3500 - 4.2600|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 24, 2019 - Oct 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.00|
Repro Med Systems, Inc. (REPR) (“the Company”) today announced a new dba name, KORU Medical Systems, which the Company will begin using in place of RMS Medical Products on October 24, 2019. Reflecting this change, the Company’s common stock will commence trading under the new ticker symbol “KRMD” on the NASDAQ effective October 24, 2019. The Company announced the rebranding on the eve of this year’s Immunoglobulin National Society Conference (IgNS 2019) in Las Vegas, Nevada, a unique, multi-disciplinary gathering of nurses, pharmacists, physicians, and Ig industry leaders.
Repro Med Systems, Inc. dba RMS Medical Products today announced that its common stock has been approved for listing and is expected to begin trading on the NASDAQ Capital Market on October 17, 2019 under the current symbol “REPR”.
Repro Med Systems, Inc. dba RMS Medical Products (“RMS Medical”) (REPR) today announced that R. John Fletcher has been appointed Chairman of the Board. Mr. Fletcher succeeds Daniel S. Goldberger who has resigned as Executive Chairman of RMS Medical in connection with his appointment as Chief Executive Officer of a bioelectronic medical device company. Mr. Goldberger will remain with RMS Medical as a non-executive member of the Board of Directors.
Repro Med Systems, Inc. dba RMS Medical Products (REPR) (“RMS Medical” or “the Company”) today announced that on June 24, 2019 the United States District Court for the Eastern District of Texas (Case No. 2:15-CV-01167-JRG-RSP) issued a decision recommending that RMS Medical’s motion for summary judgement of non-infringement against EMED Technologies (“EMED”) be granted and that the case before it be dismissed. As previously reported, on June 25, 2015 EMED filed a case in the United States District Court for the Eastern District of Texas claiming patent infringement on one of its patents by the Company’s needle sets and seeking unspecified monetary damages. This case is one of several pending between RMS Medical and EMED.
Repro Med Systems, Inc. dba RMS Medical Products (REPR) (“RMS Medical”) today announced the appointment of John Toomey to the newly created position of Vice President of Growth and Innovation. Mr. Toomey brings to RMS over 30 years of medical device industry experience as an executive, patent officer, inventor, board member, and advisor. Mr. Toomey will be responsible for research and development, product innovation, and business development, and integrating these capabilities across the enterprise.
Repro Med Systems, Inc. dba RMS Medical Products today announced that Executive Chairman Dan Goldberger is scheduled to present at the 9th Annual LD Micro Invitational on June 5, 2019.
Repro Med Systems, Inc. dba RMS Medical Products (REPR) (“RMS Medical”) today announced that R. John Fletcher has been appointed as an independent member of RMS Medical’s Board of Directors. With this appointment, RMS Medical’s Board of Directors fills the vacancy created by the passing of Arthur J. Radin. Mr. Fletcher brings more than 35 years of healthcare and medical device experience to RMS Medical.
Repro Med Systems, Inc. dba RMS Medical Products (REPR) (“RMS Medical”) today announced that shareholders voted in favor of all items of business put forth at the company’s Annual Meeting of Shareholders held on April 23, 2019 in Chester, NY. Shareholders elected director nominee Kathy S. Frommer as a new, independent member of the Board of Directors succeeding Mark L. Pastreich. Shareholders also re-elected Daniel S. Goldberger, Robert T. Allen, David W. Anderson, James M. Beck, Joseph M. Manko, Jr., and Arthur J. Radin to the Board of Directors.
Repro Med Systems, Inc. dba RMS Medical Products today announced that Arthur J. Radin, a valued and trusted member of the company’s Board of Directors, died unexpectedly on April 24, 2019 at his home in New York.
Repro Med Systems, Inc. dba RMS Medical Products today announced that it will release its financial results for the first quarter ended March 31, 2019, after the close of the financial markets on Tuesday, April 30, 2019.
Repro Med Systems, Inc. dba RMS Medical Products today announced that it has received 510 clearance from the U.S. Food and Drug Administration for its HIgh-Flo Super26™ Subcutaneous Needle Sets .
CHESTER, NY / ACCESSWIRE / March 15, 2019 / Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) today announced that Dan Goldberger, Executive Chairman, will be presenting at the 29th Annual ...
LOS ANGELES, CA / ACCESSWIRE / March 12 , 2019 / LD Micro, a company that puts on conferences for micro-cap and small-cap companies will be hosting 46 companies on March 12th (that's today) and 13th, starting ...
CHESTER, NY / ACCESSWIRE / February 21, 2019 / Repro Med Systems, Inc. dba RMS Medical Products (RMS Medical) (OTCQX: REPR) today announced that Brian Schiller, PhD, has been hired as the Vice President ...
Reported record 2018 revenue of $17.4 million, up 12.4% compared to 2017 Improved 2018 Profitability; improved Gross Margin, record Net Income and Adjusted EBITDA Significant progress made in strengthening ...
Don Pettigrew promoted to President and Chief Executive Officer Reconstituted Board of Directors approves management's strategic growth initiative to become the leading subcutaneous drug delivery partner ...
CHESTER, NY / ACCESSWIRE / December 17, 2018 / Repro Med Systems, Inc. dba RMS Medical Products ("RMS" or the "Company") (REPR) today announced that certain of its stockholders (the "Selling Stockholders") including Mr. Andy Sealfon and Dr. Paul Mark Baker, both Directors of the Company, entered into an agreement for the private placement sale of 11,101,697 shares of the Company's common stock at a price of $1.20 per share. Purchasers in the transaction included new institutional investors and an existing affiliate of the Company.